|
Dear [first name],
The past five years have seen an increased number of clinical studies in both cell and gene therapies.
The increasing pipeline carries high hopes to improve and save the lives of patients with severe diseases all over the world. Biopharmaceutical and pharmaceutical companies are committed to answer efficiently the growing market demand for targeted therapies and biopharmaceutical drugs to make those hopes a reality.
As a biopharmaceutical or pharmaceutical company developing targeted therapies, are you looking for a reliable CDMO partner to secure your viral vector manufacturing?
With 20+ years of experience in viral vectors manufacturing, Novasep offers a global and integrated offer from vector development to final product release for both clinical and commercial needs.
Find out how our expertise can contribute to the success of your viral vector manufacturing projects:
|
